Literature DB >> 11254233

A comparison between septic bursitis caused by Staphylococcus aureus and those caused by other organisms.

J C Cea-Pereiro1, J Garcia-Meijide, A Mera-Varela, J J Gomez-Reino.   

Abstract

Septic bursitis is an infection that usually involves olecranon and prepatellar bursae. Staphylococcus aureus is responsible for around 80% of cases. However, information regarding bursitis caused by non-Staphylococcus aureus microorganisms (NSAB) is scant. In this paper we describe the characteristics of NSAB and emphasise differences between these and Staphylococcus aureus bursitis (SAB). A retrospective study of all cases with septic bursitis seen between January 1991 and June 1998 at one university hospital was conducted. Only cases in which bursal fluid culture yielded growth of a microorganism were analysed. A literature review was conducted for completeness. Fifty-seven episodes of septic bursitis in 56 patients were studied: 47 of these were caused by Staphylococcus aureus and 11 by non-Staphylococcus aureus microorganisms. Forty-three SAB patients were male (91%). Mean age at diagnosis was 50 years (range 20-85 years). The presentation of bursitis had a seasonal trend, with a peak in the summer. Twenty-three patients (51%) had occupations involving frequent or sustained pressure on the bursae. Other risk factors were recent trauma in 11 (23%), alcoholism in six (13%), pre-existing bursal disease in five (11%), and chronic obstructive pulmonary disease in four (9%). There were 20 cases of olecranon bursitis (43%), 25 of prepatellar bursitis (53%) and two of first metatarsophalangeal bursitis. Characteristics of patients from the literature review were similar. Eight NSAB patients (73%) were male. Mean age at diagnosis was 46.9 (range 29-83 years). Two patients were plumbers and one a stonemason. Five (45%) had neither putative systemic nor local risk factors. There were five olecranon (45%), five prepatellar (45%), and one external malleolus bursitis. Infection by a mixed flora was common. Unlike SAB, the presentation of cases did not have a seasonal trend. The clinical spectrum of non-Staphylococcus aureus bursitis (NSAB) differs from that of Staphylococcus Aureus bursitis (SAB), and this should be considered in the initial diagnosis of septic bursitis.

Entities:  

Mesh:

Year:  2001        PMID: 11254233     DOI: 10.1007/s100670170096

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

1.  Clinical characteristics and outcomes of septic bursitis.

Authors:  Sarah B Lieber; Mary Louise Fowler; Clara Zhu; Andrew Moore; Robert H Shmerling; Ziv Paz
Journal:  Infection       Date:  2017-05-29       Impact factor: 3.553

Review 2.  [Treatment of traumatic lesions of the bursa olecrani and chronic bursitis olecrani].

Authors:  D Saul; K Dresing
Journal:  Oper Orthop Traumatol       Date:  2017-06       Impact factor: 1.154

3.  [Soft-tissue defects following olecranon bursitis. Treatment options for closure].

Authors:  H-G Damert; S Altmann; W Schneider
Journal:  Chirurg       Date:  2009-05       Impact factor: 0.955

4.  Recent developments in septic bursitis.

Authors:  Jennifer A Hanrahan
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

5.  Management of septic and aseptic prepatellar bursitis: a systematic review.

Authors:  Oliver S Brown; T O Smith; T Parsons; M Benjamin; C B Hing
Journal:  Arch Orthop Trauma Surg       Date:  2021-03-15       Impact factor: 2.928

6.  Septic bursitis in an 8-year-old boy.

Authors:  Panagiotis Kratimenos; Ioannis Koutroulis; Dante Marconi; Jennifer Ding; Christos Plakas; Margaret Fisher
Journal:  Case Rep Pediatr       Date:  2014-05-13

7.  Septic Infrapatellar Bursitis in an Immunocompromised Female.

Authors:  Kenneth Herring; Seth Mathern; Morteza Khodaee
Journal:  Case Rep Orthop       Date:  2018-06-06

8.  Meningococcal Bursitis.

Authors:  Rentaro Oda; Yoshiyuki Sekikawa; Igen Hongo
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.